These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 6639837)

  • 1. Prediction of maintenance oral theophylline dosage using single oral doses in patients with obstructive airways disease.
    Taylor DR; Kinney CD; McDevitt DG
    Br J Clin Pharmacol; 1983 Nov; 16(5):511-6. PubMed ID: 6639837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of optimum oral theophylline dose in patients with obstructive airways disease.
    Taylor DR; Kinney CD; McDevitt DG
    Br J Clin Pharmacol; 1983 Jun; 15(6):689-94. PubMed ID: 6871068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circadian variation in plasma theophylline concentrations during maintenance therapy with a sustained-release preparation in patients with obstructive airways disease.
    Taylor DR; Duffin D; Kinney CD; McDevitt DG
    Br J Clin Pharmacol; 1984 Jul; 18(1):27-30. PubMed ID: 6743488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daily maintenance dose of a long-acting theophylline from a single theophylline serum level.
    Goldstein RS; Allen LC; Thiessen JJ; Michalko K; Dayneka N; Woolf CR
    Chest; 1986 Jan; 89(1):103-8. PubMed ID: 3940768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-daily dosing of a new ultrasustained-release theophylline preparation.
    Van den Brande P; Nys J; Tjandramaga TB; Verhelst F; Demedts M
    Respiration; 1987; 52(2):144-53. PubMed ID: 3671893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of erythromycin stearate on serum theophylline concentration in patients with chronic obstructive lung disease.
    Stults BM; Felice-Johnson J; Higbee MD; Hardigan K
    South Med J; 1983 Jun; 76(6):714-8. PubMed ID: 6857302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose response relation to oral theophylline in severe chronic obstructive airways disease.
    Chrystyn H; Mulley BA; Peake MD
    BMJ; 1988 Dec; 297(6662):1506-10. PubMed ID: 3147048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individualized aminophylline therapy in patients with obstructive airway disease: oral dosage prediction from an intravenous test dose.
    Horai Y; Ishizaki T; Sasaki T; Watanabe M; Kabe J
    Eur J Clin Pharmacol; 1982; 23(2):111-21. PubMed ID: 7140800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single oral dose method for predicting steady state theophylline concentrations in clinical practice.
    Mann JS; Fitzpatrick RW; Jones PW; Prowse K; Mucklow JC; Cole RB
    Respir Med; 1990 Nov; 84(6):479-84. PubMed ID: 2274687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative dose study of a theophylline sustained-release tablet formulation after repeated administrations.
    Cova D; Cuglituri G; Rossini L; Bonfardeci G
    Int J Clin Pharmacol Ther Toxicol; 1989 Jun; 27(6):273-5. PubMed ID: 2737795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of absorption rate models in the prediction of steady-state plasma concentrations during oral theophylline administration.
    Paterson CM; Hudson SA; Jefferson GC
    J Clin Pharm Ther; 1987 Feb; 12(1):39-46. PubMed ID: 3449562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individualization of oral theophylline dosage in elderly patients.
    Talseth T; Kornstad S; Boye NP; Bredesen JE
    Acta Med Scand; 1981; 210(6):489-92. PubMed ID: 7331897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of dose dependent kinetics of theophylline.
    Brown PJ; Dusci LJ; Shenfield GM
    Eur J Clin Pharmacol; 1983; 24(4):525-7. PubMed ID: 6861868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained serum theophylline concentrations during chronic twice daily administration of a slow release preparation.
    Jackson SH; Wright JM
    Eur J Clin Pharmacol; 1983; 24(2):205-8. PubMed ID: 6840168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical utility of the single point method for theophylline maintenance dose prediction.
    Abad J; Pastor A; Prieto L; Palop J; Jiménez Torres V; Castro J
    Allergol Immunopathol (Madr); 1987; 15(6):355-9. PubMed ID: 3445876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance oral theophylline therapy: suggested schedule in elderly patients.
    Krivoy N; Alroy G
    Respiration; 1980; 40(4):233-6. PubMed ID: 7221195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience with theophylline. Relarionships between dosage, serum concentration, and toxicity.
    Jacobs MH; Senior RM; Kessler G
    JAMA; 1976 May; 235(18):1983-6. PubMed ID: 946508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intersubject variability in plasma theophylline levels after oral and intravenous administration in Jordanian patients with chronic obstructive pulmonary disease.
    Samara N; Sliman N; Sai'd S; Awidi A; Al-Turk W; Othman S; Khalaf R; Shaheen O
    Ther Drug Monit; 1988; 10(2):144-6. PubMed ID: 3381229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recommended standard theophylline doses are inadequate in chronic obstructive pulmonary disease.
    Savage J; Wiseman IC
    S Afr Med J; 1987 Apr; 71(8):508-9. PubMed ID: 3563816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical use of controlled-release theophylline in chronic airways obstruction.
    Dal Negro R; Turco P; Pomari C; Cordaro CI
    J Int Med Res; 1987; 15(6):391-6. PubMed ID: 3436486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.